RxDoctor Payments Data

Lev Goldiner, MD

Neurology · New Hartford, NYNPI 1710146733

Payments from drug & device makers

$221,291in general payments, 2019–2025

Across 1,929 payments — averaging $114.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$81K
  • EMD Serono, Inc.$45K
  • Sanofi$24K
  • Teva Pharmaceuticals USA, Inc.$20K
  • Pfizer$14K
  • Biohaven Pharmaceuticals, Inc.$7K
  • plus $30K from 54 others

What the payments were for

  • Consulting fees$9,7854%
  • Speaking & faculty fees$171,81278%
  • Travel & lodging$5,9683%
  • Food & beverage$33,21715%
  • Education$5090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)260$80,910
EMD Serono, Inc.149$45,328
Sanofi84$24,477
Teva Pharmaceuticals USA, Inc.131$19,594
Pfizer88$14,065
Biohaven Pharmaceuticals, Inc.47$7,112
Biohaven Pharmaceutical Holding Company Ltd.45$5,744
Avanir Pharmaceuticals, Inc.26$5,345
UCB, Inc.80$1,618
SK Life Science, Inc.77$1,232
AstraZeneca48$1,131
Novartis63$1,091
Lilly USA, LLC67$1,024
Bristol Myers Squibb55$851
Argenx US, Inc.45$835
Amneal Pharmaceuticals LLC44$750
Biogen39$717
Eisai Inc.29$645
Lundbeck LLC32$583
Otsuka America Pharmaceutical, Inc.28$577
ANI Pharmaceuticals, Inc.29$503
Genentech USA, Inc.32$484
Amgen(2 entities)27$483
Supernus Pharmaceuticals, Inc.87$478
Neurocrine Biosciences, Inc.25$440
Kyowa Kirin, Inc.29$431
TG Therapeutics, Inc.18$408
Mallinckrodt Hospital Products Inc.19$408
Catalyst Pharmaceuticals, Inc.20$381
Sumitomo Pharma America, Inc.27$341
Neurelis, Inc.11$270
MDD US Operations, LLC15$218
Sunovion Pharmaceuticals Inc.19$209
Jazz Pharmaceuticals Inc.9$200
E.r. Squibb & Sons, L.L.C.4$182
Adamas Pharmaceuticals, Inc.11$166
Acorda Therapeutics, Inc8$162
CSL Behring8$133
Radius Health, Inc.5$132
Johnson & Johnson6$117
Mallinckrodt Enterprises LLC6$112
Livanova USA, Inc.6$110
Tanabe Pharma America, Inc.7$108
Takeda Pharmaceuticals U.S.A., Inc.5$101
Averitas Pharma Inc.4$96
Upsher-smith Laboratories LLC5$94
Greenwich Biosciences, Inc.6$93
Arbor Pharmaceuticals, Inc.5$83
Avion Pharmaceuticals6$76
Akcea Therapeutics, Inc.4$70
Boston Scientific1$69
Merz Pharmaceuticals, LLC3$57
Boehringer Ingelheim2$48
Acadia Pharmaceuticals Inc2$46
Alnylam Pharmaceuticals Inc.2$38
Axsome Therapeutics, Inc.2$35
Sanofi-aventis U.S. LLC1$24
GE HealthCare2$22
PTC Therapeutics, Inc.1$21
Medtronic1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$221,291 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$153,113
Medicare patients
783
Services billed
2,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab53$491,942
AubagioTeriflunomide40$388,163
CopaxoneGlatiramer Acetate54$291,711
Avonex Pen (4 Pack)Interferon Beta-1a24$245,246
Nurtec OdtRimegepant Sulfate137$175,753
Teriflunomide74$161,601
AmpyraDalfampridine28$123,241
QuliptaAtogepant95$115,218
BetaseronInterferon Beta-1b13$110,831
Aimovig AutoinjectorErenumab-Aooe131$109,566
AustedoDeutetrabenazine20$108,095
Avonex (4 Pack)Interferon Beta-1a13$93,933
Dalfampridine ErDalfampridine69$59,955
BriviactBrivaracetam24$42,091
NuedextaDextromethorphan Hbr/Quinidine23$37,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$19,594$399,80674 claims
SanofiAubagio$24,477$388,16340 claims
PfizerNurtec Odt$14,065$175,753137 claims
AbbVieQulipta, Ubrelvy$80,910$136,790119 claims
Acorda Therapeutics, IncAmpyra$162$123,24128 claims
BiogenAvonex (4 Pack)$717$93,93313 claims
UCB, Inc.Briviact, Neupro$1,618$66,62142 claims
Avanir Pharmaceuticals, Inc.Nuedexta$5,345$37,88523 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$478$32,98211 claims
Otsuka America Pharmaceutical, Inc.Rexulti$577$30,52018 claims
Sunovion Pharmaceuticals Inc.Aptiom$209$15,02511 claims
Upsher-smith Laboratories LLCTopiramate$94$6,256425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →